Apr 18, 2019 | Uncategorised
On April 16, 2019 the National Institute for Health and Care Excellence (NICE) releases its final guidance recommending inotersen (Tegsedi) be placed on England’s National Health Service for the treatment of nerve damage from hereditary transthyretin-mediated...
Mar 25, 2019 | Uncategorised
L’INESSS in Québec is evaluating inotersen (Tegsedi – Akcea Therapeutics Canada) a treatment for adults with hATTR amyloidosis polyneuropathy. L’INESSS does this evaluation to determine whether to recommend the drug for reimbursement by the Québec government....
Mar 19, 2019 | Uncategorised
Alnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk. Click here to find out more.
Feb 25, 2019 | Uncategorised
If you are a person living with hATTR amyloidosis, or a caregiver for a person living with hATTR amyloidosis, we would greatly appreciate it if you could take 15 minutes to complete a questionnaire regarding Tegsedi, a medication recently approved by Health Canada....
Feb 24, 2019 | Uncategorised
Rare Disease Day is held on the last day of February each year to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To learn more, or to get involved, please visit their...
Feb 23, 2019 | Uncategorised
The Amyloidosis Foundation is working to increase awareness of all forms of amyloidosis, declaring March as Amyloidosis Awareness Month. To learn more, or to get involved, please visit the website.
Feb 22, 2019 | Uncategorised
Akcea and Ionis Announce Approval of Tegsedi (inotersen injection) in Canada. To learn more, please visit the website.
Feb 21, 2019 | Uncategorised
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis. To learn more, please visit the website.
